Teleflex Incorporated (TFX) Guidance & Earnings Results

On 2026-08-06 Teleflex Incorporated lowered guidance: "GAAP revenue growth guidance reduced to 13.4%-14.4%; pro forma adjusted constant currency revenue growth reduced to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

TFXTeleflex IncorporatedFollow TFX — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 5.8B
P/E TTM: —
Dividend yield: 1.0%
52-week: —
Next earnings: 5 Nov, in 12 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Aug 26	Lowered	GAAP revenue growth guidance reduced to 13.4%-14.4%; pro forma adjusted constant currency revenue growth reduced to 3.5%-4.5% · full year
26 Feb 26	Mixed	GAAP revenue growth 14.4%-15.4%; pro forma adjusted constant currency growth 4.5%-5.5%; adjusted EPS $6.25-$6.55. · full year
8 Jan 26	Lowered	From $3.305-$3.320B to $3.270-$3.278B · full year
6 Nov 25	Lowered	Adjusted constant currency revenue growth lowered to 6.9%-7.4% from prior · full year
31 Jul 25	Raised	FY2025 GAAP revenue growth raised to 9.00%-10.00% from 1.28%-2.28%; adjusted constant currency revenue growth raised to 7.70%-8.70%; GAAP EPS from continuing operations raised to $6.73-$7.13; adjusted diluted EPS from continuing operations raised to $13.90-$14.30 · full year

Teleflex Incorporated — questions

What guidance did Teleflex Incorporated give?: On 2026-08-06: "GAAP revenue growth guidance reduced to 13.4%-14.4%; pro forma adjusted constant currency revenue growth reduced to 3.5%-4.5%"
When does Teleflex Incorporated report earnings?: Teleflex Incorporated's next earnings report is expected on 2026-11-05.

Every figure on this page comes from Teleflex Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.